羚锐制药(600285) - 2021 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2021 was ¥697,553,750.78, representing a year-on-year increase of 21.34%[8] - The net profit attributable to shareholders for Q3 2021 was ¥107,069,514.37, an increase of 16.13% compared to the same period last year[8] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥103,777,266.82, up 18.67% year-on-year[8] - The basic earnings per share for Q3 2021 was ¥0.189, reflecting a growth of 16.67% compared to the previous year[12] - Total operating revenue for the first three quarters of 2021 reached ¥2,053,040,234.42, an increase of 17.4% compared to ¥1,749,409,044.15 in the same period of 2020[38] - Net profit for the first three quarters of 2021 was ¥327,555,622.87, representing a growth of 22.0% compared to ¥268,309,852.21 in 2020[43] - The company reported a total profit of ¥376,322,413.97, an increase of 19.6% from ¥314,683,087.91 in the same period of 2020[43] Assets and Liabilities - The total assets at the end of Q3 2021 amounted to ¥3,715,555,734.23, an increase of 7.46% from the end of the previous year[12] - As of September 30, 2021, the company's total assets reached RMB 3,715,555,734.23, an increase from RMB 3,457,756,227.25 as of December 31, 2020, representing a growth of approximately 7.46%[29] - Total current liabilities increased to RMB 1,389,245,214.96 from RMB 1,066,257,112.24, reflecting a rise of approximately 30.3%[35] - The total equity attributable to shareholders at the end of Q3 2021 was ¥2,243,078,725.55, a decrease of 3.01% compared to the previous year[12] - Total liabilities amounted to approximately $1.14 billion, with a slight increase from the previous period[56] - Non-current liabilities totaled approximately $69.34 million, reflecting an increase of about $8.41 million[56] Cash Flow - The net cash flow from operating activities for the year-to-date was ¥628,695,178.32, showing an increase of 85.92%[12] - Cash inflow from operating activities totaled ¥2,493,773,487.81, a significant increase from ¥1,901,664,281.56 in the previous year[45] - The net cash flow from operating activities increased to ¥628,695,178.32, up from ¥338,148,814.79, representing an 86% increase year-over-year[49] - The net cash flow from investing activities was negative at -¥172,423,104.56, worsening from -¥60,773,584.28 in the previous year[49] - Cash inflow from financing activities totaled ¥235,906,400.00, an increase from ¥171,511,000.00 in the prior year[49] - Cash outflow for operating activities totaled ¥1,865,078,309.49, compared to ¥1,563,515,466.77, indicating a 19.3% increase[49] - The company reported a significant increase in tax payments, totaling ¥282,751,594.30, up from ¥241,435,349.15, which is a 17% increase[49] Shareholder Information - The company had a total of 34,572 common shareholders at the end of the reporting period[19] - The company repurchased a total of 19,086,325 shares, accounting for 3.36% of the total share capital, with a total expenditure of RMB 184,472,831.57 as of September 30, 2021[24] - The company completed the transfer of 2,159,400 shares under the employee stock ownership plan and granted 13,720,600 shares of restricted stock as part of its incentive plan[25] Expenses - Research and development expenses rose to ¥62,042,225.21, up 24.8% from ¥49,662,393.86 in the same period last year[38] - Sales expenses increased to ¥992,923,866.20, compared to ¥873,153,976.85 in the previous year, marking a rise of 13.7%[38] Accounting Policies - The company adopted the new leasing standards effective January 1, 2021, impacting the recognition of right-of-use assets and lease liabilities[57] - The accounting policy change is not expected to significantly affect the company's financial position, operating results, or cash flows[59] - The company confirmed the recognition of depreciation and interest expenses for all leased assets, excluding short-term and low-value leases[57] - The board of directors announced that the accounting policy change does not harm the interests of the company and its shareholders[59] Other Financial Metrics - The company's cash and cash equivalents amounted to RMB 929,602,638.19, up from RMB 732,316,860.77 in the previous year, indicating a year-over-year increase of about 27.0%[29] - The company's inventory as of September 30, 2021, was RMB 389,545,855.71, compared to RMB 331,412,309.59 at the end of 2020, marking an increase of around 17.5%[29] - The company's accounts receivable increased to RMB 269,562,213.59 from RMB 145,719,962.51, representing a significant growth of approximately 84.8%[29] - The company's long-term equity investments rose to RMB 116,572,532.76 from RMB 98,580,891.15, reflecting an increase of about 18.3%[33] - The company reported a total of RMB 934,975,900.94 in other payables, which increased from RMB 662,066,894.27, indicating a rise of approximately 41.1%[35] - Deferred income amounted to approximately $48.26 million, indicating stable revenue recognition practices[56] - The company maintains undistributed profits of approximately $1.13 billion, reflecting strong retained earnings[56]